Hepato‐biliary clinical trials and their inclusion in the Cochrane Hepato‐Biliary Group register and reviews

Klingenberg, Sarah Louise; Nikolova, Dimitrinka; Alexakis, N.; Als‐Nielsen, Bodil; Colli, Agostino; Conte, Dario; D’Amico, Gennaro; Davidson, Brian R; Fingerhut, Abe; Fraquelli, Mirella; Gluud, Lise Lotte; Gurusamy, Kurinchi Selvan; Keus, Frederik; Khan, Saboor; Koretz, Ronald L.; Laarhoven, Cornelis J. H. M. van; Liu, Jianping; Myers, Robert J.; Pagliaro, Luigi; Simonetti, Rosa G; Thorlund, Kristian; Gluud, Christian

doi:10.1111/j.1440-1746.2010.06465.x

Cited by 4 publications

(2 citation statements)

References 70 publications

(117 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The instructions given in the Cochrane Handbook for Systematic Reviews of Interventions and the Cochrane Hepato-Biliary Group Module were followed. 11,12 …”

Section: Methodsmentioning

confidence: 99%

Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Rustagi

Njei

2015

Pancreas

View full text Add to dashboard Cite

Objectives To identify the factors affecting the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing post–endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). Methods We systematically searched databases for relevant studies published from inception to November 2013. Results A meta-analysis of 11 randomized trials (n = 2497) revealed a significant reduction in PEP in patients who received NSAIDs compared with that in patients who received placebo (relative risk [RR], 0.59; 95% confidence interval [CI], 0.41–0.85; P = 0.005). In subgroup analysis by treatment type, indomethacin had no significant effect (RR, 0.66; 95% CI, 0.38–1.15; P = 0.14), whereas other NSAIDs showed significant benefit (RR, 0.51; 95% CI, 0.29–0.91; P = 0.02). Only rectal administration significantly reduced the incidence of PEP (RR, 0.43; 95% CI, 0.32–0.58; P < 0.00001). The risk for PEP was the lowest among patients who received NSAIDs before ERCP (RR, 0.48; 95% CI, 0.29–0.78; P = 0.003). NSAIDs did not significantly reduce the risk of PEP in men (RR, 0.61; 95% CI, 0.34–1.09), patients with sphincter of Oddi dysfunction (RR, 0.98; 95% CI, 0.38–2.54), or patients with pancreatic duct injection (RR, 0.64; 95% CI, 0.35–1.18). Conclusions Rectal administration of NSAIDs (especially diclofenac), before ERCP, seemed to be the most effective strategy for preventing PEP.

show abstract

“…The instructions given in the Cochrane Handbook for Systematic Reviews of Interventions and the Cochrane Hepato-Biliary Group Module were followed. 11,12 …”

Section: Methodsmentioning

confidence: 99%

Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Rustagi

Njei

2015

Pancreas

View full text Add to dashboard Cite

show abstract

“…Some of The CHBG reviews may include on average five or six randomised trials per outcome, but these reviews may still lack firm conclusions, as the traditional metaanalyses used to analyse the data for the review outcomes suffer from type I and type II errors. 4 Such errors may occur due to random errors because of sparse data or because of repetitive testing of the trial data, as the cumulative metaanalysis implies addition of new trials. To control for type I and type II errors and being inspired by the methodology used for interim analyses of a single trial, The CHBG in close collaboration with The Copenhagen Trial Unit (http:// www.ctu.dk) (also hosting The CHBG Editorial Team Office) www.actamedicaportuguesa.com Nikolova D, et al The cochrane hepato-biliary group as a resource of evidence-based medicine, Acta Med Port 2013 Mar-Apr;26(2):81-82 has developed methodology of trial sequential analysis (TSA) 5,6 (http://www.ctu.dk/tsa/index.html).…”

Section: Introductionmentioning

confidence: 99%

The Cochrane Hepato-Biliary Group as a Resource Example of Evidence-Based Medicine for All

2013

View full text Add to dashboard Cite

show abstract

Methods to decrease blood loss and transfusion requirements for liver transplantation

Gurusamy

Pissanou²,

Pikhart³

et al. 2011

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Aprotinin, recombinant factor VIIa, and thromboelastography groups may potentially reduce blood loss and transfusion requirements. However, risks of systematic errors (bias) and risks of random errors (play of chance) hamper the confidence in this conclusion. We need further well-designed randomised trials with low risk of systematic error and low risk of random errors before these interventions can be supported or refuted.

show abstract

Hepato‐biliary clinical trials and their inclusion in the Cochrane Hepato‐Biliary Group register and reviews

Abstract: A large amount of work has been carried out since 1996. However, there is still much to do, as the CHBG register contains a great number of RCT and CCT on topics that have not yet been systematically reviewed.

Cited by 4 publications

References 70 publications

Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis

The Cochrane Hepato-Biliary Group as a Resource Example of Evidence-Based Medicine for All

Methods to decrease blood loss and transfusion requirements for liver transplantation

Contact Info

Product

Resources

About